Overview
Immunexpress develops molecular diagnostics for rapid sepsis detection by analyzing host immune response gene expression from whole blood. Their flagship product, SeptiCyte RAPID, is a fully automated cartridge compatible with the Biocartis Idylla platform, delivering results in about one hour to differentiate sepsis from non-infectious inflammation. This technology supports clinicians in early triage and treatment decisions, improving patient outcomes and reducing healthcare costs.
Frequently asked questions
- What is SeptiCyte RAPID and how does it work?
- SeptiCyte RAPID is a cartridge-based RT-PCR test that quantifies host immune-response gene expression from whole blood to generate a sepsis likelihood score. It analyzes RNA from immune cells to detect systemic infection response faster than pathogen identification, providing results in about one hour on the Biocartis Idylla platform.
- What regulatory approvals does Immunexpress have?
- Immunexpress products like SeptiCyte RAPID have been validated through extensive clinical trials worldwide. Specific regulatory statuses such as FDA clearance or CE marking are not detailed in available information; contact Immunexpress for current approvals.
- Where does Immunexpress operate and serve geographies?
- Immunexpress is headquartered in Seattle, USA, with operations in Brisbane, Australia. Their technology targets global healthcare systems, with clinical validation from worldwide trials, supporting use in emergency departments and critical care settings internationally.